



We thank for the kind educational unrestricted support



Hotel La Palma  
Conference center – Gardenia Hall  
Corso Umberto I n. 33 - 28838 Stresa



**INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP**  
Foundation for the Institute of Oncology Research  
Ospedale Regionale di Bellinzona e Valli | Via Athos Gallino, 12 | CH-6500 Bellinzona  
Phone +41 91 811 90 40 | Fax +41 91 811 91 82 | E-mail [ielsg@eoc.ch](mailto:ielsg@eoc.ch) | [www.ielsg.org](http://www.ielsg.org)

13:30 – 14:00	<b>Registration</b>
14:00	<b>Welcome and introductory remarks</b> E. Zucca
14:15 – 15:00	<b>Educational Lecture</b> Circulating tumor DNA (ctDNA): A non-invasive diagnostic tool and outcome predictor in CNS lymphoma F. Scherer
15:00 – 16:15	<b>IELSG Study Discussion 1</b> Chair: G. Nowakowski
	<b>Marginal Zone Lymphoma (MZL) – Part I</b>
15:00	IELSG38 – A phase II study of Chlorambucil in combination with subcutaneous Rituximab followed by maintenance therapy with subcutaneous Rituximab in patients with extranodal marginal zone B-cell lymphoma of Mucosa Associated Lymphoid Tissue (MALT lymphoma) – Study final results A. Stathis
15:15	IELSG39 – International prospective phase 2 trial addressing the efficacy of first-line <i>Chlamydomydia psittaci</i> -eradicating therapy with protracted administration of doxycycline followed by eradication monitoring and antibiotic re-treatment at infection re-occurrence in patients with newly diagnosed Ocular Adnexal Marginal Zone Lymphoma (OAMZL) – Study update and results of the first analysis A Ferreri
15:30	IELSG40 – A phase II trial addressing feasibility and activity of clarithromycin + lenalidomide combination: a full oral treatment for patients with relapsed/refractory mucosa-associated lymphoid tissue (MALT) lymphoma (CLEO trial) – Study update and results of the first analysis M.C. Piroso
15:45	IELSG47 – MALIBU trial – Phase II study of combination ibrutinib and rituximab in untreated marginal zone lymphomas A. Conconi
16:00	IELSG49 – Phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated marginal zone lymphomas (MZL) A. Stathis
16:15 – 16:45	<b>Coffee Break</b>
16:45 – 18:00	<b>IELSG Study Discussion 2</b> Chair: E. Zucca
	<b>Marginal Zone Lymphoma (MZL) – Part II</b>
16:45	IELSG44 – FDG-PET evaluation for marginal zone lymphoma and its prognostic role: an international multicenter retrospective analysis (PIMENTO) S. Luminari
	<b>NK/T-cell Lymphoma</b>
17:00	IELSG50 – Pembrolizumab and radiotherapy for previously untreated patients with limited stage NK/T cell lymphoma S. Luminari
	<b>Primary and Secondary Diffuse Large B-Cell Lymphoma of the Central Nervous System (CNS)</b>
17:15	PRIMA-CNS - Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly CNS lymphoma patients – a randomized phase III trial B. Kasenda
17:30	OptiMATE – Optimizing MATRix as remission induction in PCNSL: De-escalated induction treatment in newly diagnosed primary CNS lymphoma – a randomized phase III trial T. Calimeri
17:45	IELSG45 – Randomized phase II trial on fitness- and comorbidity- tailored treatment in elderly patients with newly diagnosed primary CNS lymphoma (FIORELLA Trial) – Study update A. Ferreri
20:00	<b>Dinner</b>

08:30 – 10:15	<b>IELSG Study Discussion 3</b> Chair: F. Cavalli
	<b>Primary Mediastinal Lymphoma</b>
08:30	IELSG37 – Randomized study assessing the role of mediastinal radiotherapy after rituximab containing chemotherapy in Primary Mediastinal B-Cell Lymphoma (PMBCL) - Study update and results of the ongoing analysis M. Martelli & L. Ceriani
08:45	IELSG51 – A future IELSG study in PMBCL? E. Zucca
	<b>New Projects</b>
09:00	Follow-up on IELSG46: pathology M. Ponzoni
09:15	IELSG48 – Phase III, interventional, multicentre, open label, randomized study comparing rituximab plus zanubrutinib to rituximab monotherapy in previously untreated, symptomatic splenic marginal zone lymphoma D. Rossi
09:30	Translational study on Nodal MZL D. Rossi
09:45	Translational study on Extranodal MZL F. Bertoni
10:00	The IRAK4 inhibitor CA-4948: a new molecule with antitumor activity in a preclinical model of CNS lymphoma E. Martinez (Curis)
10:15 – 10:45	<b>Coffee Break</b>
<b>CLOSED SESSION – FOR IELSG MEMBERS ONLY</b>	
10:45 – 12:00	<b>General Assembly</b> Chair: F. Cavalli Discussion of administrative issue
12:00	<b>Closing Remarks</b>